Uncover key drivers, emerging technologies, and competitive movements shaping the covid-19 current therapy market from 2026–2035 with trusted insights from The Business Research Company
How much larger will the COVID-19 Current Therapy Market be in 2030 compared with 2026?
The covid-19 current therapy market size has observed a significant reduction in recent years. Its value is projected to fall from $2.35 billion in 2025 to $1.57 billion in 2026, exhibiting a compound annual growth rate (CAGR) of -33.2%. This historical decrease can be ascribed to several factors, including the sudden onset of covid-19, high rates of hospitalization, restricted initial therapeutic choices, declining government and healthcare initiatives, and fewer emergency approvals for medications.
The covid-19 current therapy market size is projected to experience a significant decrease over the coming years. It is predicted to fall to $0.31 billion by 2030, reflecting a compound annual growth rate (CAGR) of -33.2%. This anticipated decline throughout the forecast period stems from reduced telemedicine uptake for covid-19 management and limited growth in home care services. Key trends anticipated during this period encompass a rise in the use of antiviral and monoclonal antibody treatments, a greater application of corticosteroids for severe covid-19 scenarios, an increase in home care and remote patient monitoring for the virus, an broadening of supplement and immune support treatments, and the incorporation of combined and experimental therapies into treatment plans.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3247&type=smp
What Drivers Are Guiding Growth Patterns In The COVID-19 Current Therapy Market?
The COVID-19 current therapy market is expected to expand, driven by the ongoing development of healthcare infrastructure. The healthcare industry encompasses the economic sectors that deliver products and services aimed at curing, preventing, rehabilitating, and providing palliative care for patients. Effective healthcare infrastructure is crucial for the successful implementation of COVID-19 therapies, facilitating prompt patient care, supporting research and clinical trials, and allocating essential resources for optimal treatment delivery. For example, the American Health Care Association, a US-based nonprofit, reported in May 2023 that the number of hospitals in the US rose to 6,129 from 6,093 in 2022. Additionally, a report published in May 2023 by the UK’s Office for National Statistics indicated a substantial increase in healthcare spending in the UK, seeing a 9.4% rise in nominal terms and 9.7% in real terms. Consequently, the expansion of the healthcare industry is propelling the growth of the COVID-19 current therapy market.
Which Segments Are Driving Activity In The COVID-19 Current Therapy Market?
The covid-19 current therapy market covered in this report is segmented –
1) By Drug Type: Antiviral, Monoclonal Antibodies, Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti-Infective Drugs
2) By Route Of Administration: Oral, Intravenous
3) By End-User: Hospitals, Clinics, Home Care, Others
Subsegments:
1) By Antiviral: Remdesivir, Oseltamivir, Favipiravir, Nirmatrelvir Or ritonavir (Paxlovid)
2) By Monoclonal Antibodies: Bamlanivimab, Casirivimab Or Imdevimab (REGEN-COV), Sotrovimab, Etesevimab
3) By Corticosteroid: Dexamethasone, Hydrocortisone, Prednisone
4) By Supplements: Vitamin D, Vitamin C, Zinc, Quercetin
5) By Antimalarial: Hydroxychloroquine, Chloroquine
6) By Interferons and Interleukin Inhibitors: Interferon beta-1a, Interleukin-6 inhibitors
7) By Other Anti-Infective Drugs: Antibiotics, Antifungal Agents
What Industry Trends Are Transforming The COVID-19 Current Therapy Market?
Major companies operating in the COVID-19 current therapy market are increasingly focusing on introducing innovative products, such as COVID-19 oral antiviral treatment, to gain a competitive edge. Antiviral treatment refers to the use of medications designed to inhibit the replication and spread of viruses within the body. For instance, in April 2024, Invivyd, a US-based company dedicated to developing antibody-based therapies for serious viral infectious diseases, provided an update on the launch of PEMGARDA™. Following its emergency use authorization (EUA) from The U.S. Food and Drug Administration (FDA), PEMGARDA quickly became available for commercial use. This treatment aims to prevent COVID-19 in individuals with moderate-to-severe immune compromise.
Which Leading Companies Dominate The COVID-19 Current Therapy Market Share?
Major companies operating in the covid-19 current therapy market are Gilead Sciences Inc., Ipca Laboratories Limited, Zydus Cadila, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, AbbVie, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Wallace Pharmaceuticals Inc., Canary Health Technologies, Thermo Fisher Scientific
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report
How Does The COVID-19 Current Therapy Market Perform Across Major Global Regions?
North America is the largest region in the COVID-19 current therapy market in 2025. Middle East is expected to be the fastest-growing region in the global COVID-19 current therapy market share during the forecast period. The regions covered in the covid-19 current therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized COVID-19 Current Therapy Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3247&type=smp
Browse Through More Reports Similar to the Global COVID-19 Current Therapy Market 2026, By The Business Research Company
Hydroxychloroquines Market Report 2026
https://www.thebusinessresearchcompany.com/report/hydroxychloroquines-global-market-report
Covid 19 Detection Test Kits And Consumables Market Report 2026
Covid 19 Rapid Test Kits Market 2026
https://www.thebusinessresearchcompany.com/report/covid-19-rapid-test-kits-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model